PD-L1 (22C3) expression and prognostic implications in esophageal squamous cell carcinoma

IF 1.5 4区医学 Q3 PATHOLOGY

Annals of Diagnostic Pathology Pub Date : 2024-11-06 DOI:10.1016/j.anndiagpath.2024.152394

Zhikai Chi, Lan Peng, Dipti M. Karamchandani, Jing Xu

{"title":"PD-L1 (22C3) expression and prognostic implications in esophageal squamous cell carcinoma","authors":"Zhikai Chi, Lan Peng, Dipti M. Karamchandani, Jing Xu","doi":"10.1016/j.anndiagpath.2024.152394","DOIUrl":null,"url":null,"abstract":"<div><div>Programmed cell death-ligand 1 (PD-L1) clone 22C3 is the only Food and Drug Administration-approved companion diagnostic test for pembrolizumab for the treatment of esophageal squamous cell carcinoma (ESCC). However, prior studies conducted in Asia and Europe have used various PD-L1 antibody clones other than 22C3. We aimed to study the expression profile of PD-L1, specifically of clone 22C3, in ESCC and its significance with regards to histological features, clinical parameters, and overall survival in a case series from two large US hospital systems. PD-L1 (22C3) immunohistochemistry was performed on 82 specimens obtained from 75 patients. Electronic medical records were reviewed to obtain the clinical and follow-up data. Of these specimens, 39 % (32/82) were negative for PD-L1 (22C3) expression (combined positive score (CPS) of 0). The remaining 50 specimens were positive, with CPSs ranging from 1 to 100. Treated specimens showed decreased PD-L1 (22C3) expression compared to untreated specimens. In the multivariate Cox proportional hazards regression model, PD-L1 (22C3) expression was shown to be a favorable prognostic factor for overall survival (<em>p</em> = 0.03, hazard ratio 0.16) only when the CPSs were ≥ 25, independent of surgery, definitive chemotherapy and/or radiotherapy, immunotherapy, and initial clinical stages. We performed a comprehensive study to investigate the expression profile of PD-L1 clone 22C3 in the US patients with ESCC. Our analysis showed that PD-L1 (22C3) expression decreased in treated specimens, and a CPS of ≥25 was associated with a favorable prognosis.</div></div>","PeriodicalId":50768,"journal":{"name":"Annals of Diagnostic Pathology","volume":"74 ","pages":"Article 152394"},"PeriodicalIF":1.5000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Diagnostic Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S109291342400131X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Programmed cell death-ligand 1 (PD-L1) clone 22C3 is the only Food and Drug Administration-approved companion diagnostic test for pembrolizumab for the treatment of esophageal squamous cell carcinoma (ESCC). However, prior studies conducted in Asia and Europe have used various PD-L1 antibody clones other than 22C3. We aimed to study the expression profile of PD-L1, specifically of clone 22C3, in ESCC and its significance with regards to histological features, clinical parameters, and overall survival in a case series from two large US hospital systems. PD-L1 (22C3) immunohistochemistry was performed on 82 specimens obtained from 75 patients. Electronic medical records were reviewed to obtain the clinical and follow-up data. Of these specimens, 39 % (32/82) were negative for PD-L1 (22C3) expression (combined positive score (CPS) of 0). The remaining 50 specimens were positive, with CPSs ranging from 1 to 100. Treated specimens showed decreased PD-L1 (22C3) expression compared to untreated specimens. In the multivariate Cox proportional hazards regression model, PD-L1 (22C3) expression was shown to be a favorable prognostic factor for overall survival (p = 0.03, hazard ratio 0.16) only when the CPSs were ≥ 25, independent of surgery, definitive chemotherapy and/or radiotherapy, immunotherapy, and initial clinical stages. We performed a comprehensive study to investigate the expression profile of PD-L1 clone 22C3 in the US patients with ESCC. Our analysis showed that PD-L1 (22C3) expression decreased in treated specimens, and a CPS of ≥25 was associated with a favorable prognosis.

查看原文本刊更多论文

食管鳞状细胞癌中 PD-L1 (22C3) 的表达及其预后影响。

程序性细胞死亡配体 1（PD-L1）克隆 22C3 是美国食品和药物管理局批准的唯一用于治疗食管鳞状细胞癌（ESCC）的 pembrolizumab 伴行诊断检测。然而，之前在亚洲和欧洲进行的研究使用了 22C3 之外的各种 PD-L1 抗体克隆。我们的目的是研究PD-L1（特别是克隆22C3）在ESCC中的表达谱，以及它在组织学特征、临床参数和总生存期方面的意义。研究人员对 75 名患者的 82 份标本进行了 PD-L1 (22C3) 免疫组化。研究人员查阅了电子病历，以获得临床和随访数据。在这些标本中，39%（32/82）的 PD-L1 (22C3) 表达为阴性（综合阳性评分（CPS）为 0）。其余 50 个标本为阳性，CPS 从 1 到 100 不等。与未经治疗的标本相比，经过治疗的标本显示出较低的 PD-L1 (22C3) 表达。在多变量 Cox 比例危险回归模型中，只有当 CPS ≥ 25 时，PD-L1（22C3）表达才是总生存期的有利预后因素（p = 0.03，危险比 0.16），且不受手术、明确化疗和/或放疗、免疫治疗和初始临床分期的影响。我们对美国 ESCC 患者中 PD-L1 克隆 22C3 的表达谱进行了全面研究。我们的分析表明，PD-L1（22C3）在治疗后的标本中表达减少，CPS≥25与预后良好相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Diagnostic Pathology 医学-病理学

CiteScore

3.90

自引率

5.00%

发文量

149

审稿时长

26 days

期刊介绍： A peer-reviewed journal devoted to the publication of articles dealing with traditional morphologic studies using standard diagnostic techniques and stressing clinicopathological correlations and scientific observation of relevance to the daily practice of pathology. Special features include pathologic-radiologic correlations and pathologic-cytologic correlations.